[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Mula V, Mandal A, Britton E, Shanker VS: Direct bony invasion of malignant melanoma. Indian J Orthop; 2009 Oct;43(4):420-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct bony invasion of malignant melanoma.
  • Malignant melanoma is known to spread by local extention, by the lymphatics by the blood stream.
  • Histopathology diagnosed the lesion as locally advanced malignant melanoma.
  • Radiological investigations by X-ray and magnetic resonance imaging revealed malignant infiltration of the tibia in its mid and lower third with two soft tissue metastatic masses adjacent.
  • Histology following amputation confirmed malignant melanoma with cranial resection margin involvement.
  • She underwent a further above-knee amputation followed by chemotherapy.
  • The patient recovered from the amputation but subsequently died 6 months later due to bronchopneumonia from lung metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Orthopedics. 2001 Mar;24(3):225, 307-8 [11300284.001]
  • [Cites] J Bone Joint Surg Am. 2001 Nov;83-A(11):1713-7 [11701796.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1780-4 [11100057.001]
  • [Cites] J Laryngol Otol. 2000 May;114(5):378-80 [10912271.001]
  • [Cites] Can J Surg. 2000 Apr;43(2):137-9 [10812349.001]
  • [Cites] J Hand Surg Am. 2000 Mar;25(2):365-9 [10722831.001]
  • [Cites] Int J Clin Oncol. 2007 Aug;12(4):305-8 [17701013.001]
  • [Cites] Ear Nose Throat J. 2007 Jul;86(7):388-90 [17702316.001]
  • [Cites] J Cutan Med Surg. 2006 Jan-Feb;10(1):36-40 [17241571.001]
  • [Cites] Europace. 2006 Jul;8(7):545-8 [16798769.001]
  • [Cites] Am Surg. 2006 Jan;72(1):98-100 [16494196.001]
  • [Cites] J Hand Surg Am. 2005 May;30(3):615-9 [15925176.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):336-44 [10379853.001]
  • [Cites] Arch Pathol Lab Med. 1999 Feb;123(2):163-6 [10050793.001]
  • [Cites] J Laryngol Otol. 2004 May;118(5):382-4 [15165318.001]
  • [Cites] J Hand Surg Am. 2004 Mar;29(2):194-200 [15043888.001]
  • [Cites] Clin Nucl Med. 2003 Dec;28(12):961-5 [14663316.001]
  • [Cites] Mol Imaging Biol. 2002 Oct;4(5):359-62 [14537111.001]
  • [Cites] Rom J Gastroenterol. 2002 Mar;11(1):53-6 [12096315.001]
  • [Cites] J Hand Surg Am. 2000 Nov;25(6):1169-72 [11119681.001]
  • (PMID = 19838397.001).
  • [ISSN] 1998-3727
  • [Journal-full-title] Indian journal of orthopaedics
  • [ISO-abbreviation] Indian J Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2762569
  • [Keywords] NOTNLM ; Bone tumor / direct invasion / malignant melanoma / metastatic melanoma
  •  go-up   go-down


2. Misaki H, Yamauchi T, Arai H, Yamamoto S, Sutoh H, Yoshida A, Tsutani H, Eguchi M, Nagoshi H, Naiki H, Baba H, Ueda T, Yamakawa M: Secondary malignant fibrous histiocytoma following refractory langerhans cell histiocytosis. J Clin Exp Hematop; 2009 May;49(1):33-7
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary malignant fibrous histiocytoma following refractory langerhans cell histiocytosis.
  • We describe a rare case of secondary malignant fibrous histiocytoma (MFH) following Langerhans cell histiocytosis (LCH).
  • A 23-year-old Japanese male exhibited systemic lymphadenopathy, multiple lung tumors, and osteolytic changes in bilateral iliac bones in 1989.
  • A biopsy specimen from the left iliac bone revealed an infiltration of S-100 protein-positive histiocyte-like cells intermingled with eosinophils, which confirmed the diagnosis of eosinophilic granuloma, a type of LCH.
  • Although the patient was treated with prednisolone initially, the disease did not respond well and progressed gradually over time.
  • The patient subsequently received multiple courses of chemotherapy and immunosuppressive therapy with many kinds of anticancer agents for 6 years.
  • He also received radiotherapy totaling 136.8 Gy for lung tumors and osteolytic lesions of the pelvis.
  • Although chemotherapy was continued, the patient died of pneumonia during the neutropenic period following chemotherapy.
  • LCH was not detected histologically in any tissues.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / diagnosis. Histiocytosis, Langerhans-Cell / diagnosis
  • [MeSH-minor] Bone Diseases. Eosinophilic Granuloma / diagnosis. Eosinophilic Granuloma / drug therapy. Eosinophilic Granuloma / radiotherapy. Fatal Outcome. Humans. Lung Diseases. Male. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / etiology. Pneumonia. Salvage Therapy / methods. Young Adult

  • Genetic Alliance. consumer health - Histiocytosis.
  • Genetic Alliance. consumer health - Langerhans cell histiocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474515.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Martín Díaz E, Arnau Obrer A, Martorell Cebollada M, Cantó Armengod A: [Thoracocentesis for the assessment of lung cancer with pleural effusion]. Arch Bronconeumol; 2002 Oct;38(10):479-84
Hazardous Substances Data Bank. TALC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thoracocentesis for the assessment of lung cancer with pleural effusion].
  • [Transliterated title] La toracocentesis en la evaluación del cáncer de pulmón con derrame pleural
  • OBJECTIVE: To analyze the pleural and mediastinal effect of thoracentesis tumor-positive cytology in pleural effusions (PE) detected by chest X ray of lung cancer patients.
  • PATIENTS AND METHODS: The study was performed in patients with lung cancer for whom PE was evident in chest X ray films, who then underwent thoracentesis followed by video-assisted thoracoscopy (VAT) to evaluate direct pleural tumor infiltration, mediastinal node involvement and the existence of pleural metastasis.
  • Patients without contraindication underwent the procedure, even if tumor positive cytology was present.
  • When pleural metastasis was found the treatment employed was talc pleurodesis and chemotherapy.
  • Descriptive statistics were compiled and the validity of VAT for pleural metastasis diagnosis, of thoracentesis pleural cytology to detect infiltration of the tumor-adyacent pleura, N2 disease and pleural metastasis were calculated.
  • RESULTS: PE was present in 188 of 971 consecutive lung cancer patients.
  • For the evaluation of adjacent pleura infiltration, without pleural metastasis, the sensitivity of cytology was 40%, specificity 100%, PPV 100% and NPV 25%.
  • Survival after thoracotomy was 39% after 2 years, and the median survival time was 14.5 months.
  • CONCLUSIONS: Nineteen percent of patients with lung cancer have PE, of which 7% can be seen in chest X ray films.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Lung Neoplasms / complications. Pleural Effusion / diagnosis. Pleural Effusion / etiology. Pleural Neoplasms / diagnosis. Pleural Neoplasms / secondary. Thoracoscopy. Thoracotomy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Cohort Studies. Cytodiagnosis. Female. Humans. Male. Middle Aged. Paracentesis. Pleura / pathology. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / pathology. Pleurodesis. Prospective Studies. Sensitivity and Specificity. Survival Analysis. Talc / administration & dosage. Thoracic Surgery, Video-Assisted. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12372198.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 14807-96-6 / Talc
  •  go-up   go-down


Advertisement
4. Wendt MK, Schiemann WP: Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res; 2009;11(5):R68
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
  • METHODS: FAK expression and activity were inhibited in normal and malignant mammary epithelial cells (MECs) either genetically by using lentiviral-mediated delivery of shRNAs against FAK, or pharmacologically through in vitro and in vivo use of the FAK inhibitors, PF-562271 and PF-573228.
  • Finally, in contrast to FAK depletion, adjuvant FAK chemotherapy of mammary tumors decreased their growth in part by diminished macrophage tumor infiltration.
  • Furthermore, this study establishes chemotherapeutic targeting of FAK as an effective, two-pronged approach in preventing tumor progression both by decreasing innate immune cell infiltration, and by inhibiting early TGF-beta-dependent metastasis.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Oct 15;86(8):1551-6 [10526262.001]
  • [Cites] N Engl J Med. 2000 May 4;342(18):1350-8 [10793168.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2417-23 [10873094.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1717-30 [11058615.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(2):101-10 [11261825.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):67-82 [11467453.001]
  • [Cites] Curr Opin Genet Dev. 2002 Feb;12(1):22-9 [11790550.001]
  • [Cites] J Clin Invest. 2003 Oct;112(7):1116-24 [14523048.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):807-21 [14557817.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):229-39 [15050954.001]
  • [Cites] J Korean Med Sci. 2004 Oct;19(5):710-5 [15483349.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):93-101 [8514065.001]
  • [Cites] J Cell Biol. 1994 Dec;127(6 Pt 2):2021-36 [7806579.001]
  • [Cites] Nature. 1995 Oct 12;377(6549):539-44 [7566154.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] Nat Biotechnol. 1997 Sep;15(9):871-5 [9306402.001]
  • [Cites] Head Neck. 1998 Oct;20(7):634-9 [9744465.001]
  • [Cites] J Cell Sci. 1999 Aug;112 ( Pt 16):2677-91 [10413676.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Dec;12(4):342-5 [15536334.001]
  • [Cites] Breast Cancer Res Treat. 2004 Nov;88(2):109-16 [15564794.001]
  • [Cites] Br J Cancer. 2005 Sep 19;93(6):694-8 [16136050.001]
  • [Cites] Oncogene. 2006 Jul 27;25(32):4429-40 [16547501.001]
  • [Cites] Lung Cancer. 2006 Sep;53(3):263-71 [16842883.001]
  • [Cites] Oncogene. 2006 Sep 28;25(44):5969-84 [16682956.001]
  • [Cites] Breast Cancer Res. 2006;8(4):R42 [16859511.001]
  • [Cites] Ann N Y Acad Sci. 2006 Nov;1089:119-26 [17261761.001]
  • [Cites] Biochem Pharmacol. 2007 Mar 1;73(5):597-609 [16997283.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3752-8 [17440088.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 May;7(5):609-11 [17492924.001]
  • [Cites] J Biol Chem. 2007 May 18;282(20):14845-52 [17395594.001]
  • [Cites] Mol Biol Cell. 2007 Jun;18(6):2169-78 [17409352.001]
  • [Cites] J Cell Sci. 2007 Dec 1;120(Pt 23):4230-40 [18032789.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Exp Cell Res. 2008 Jan 1;314(1):143-52 [17949712.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20302-7 [18056629.001]
  • [Cites] Mol Cell. 2008 Jan 18;29(1):9-22 [18206965.001]
  • [Cites] Oncogene. 2008 Feb 28;27(10):1461-71 [17724466.001]
  • [Cites] Oncogene. 2008 Feb 28;27(10):1439-48 [17828307.001]
  • [Cites] Carcinogenesis. 2008 Feb;29(2):244-51 [18174260.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1462-70 [18316610.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1935-44 [18339875.001]
  • [Cites] Nat Cell Biol. 2008 Oct;10(10):1199-207 [18758450.001]
  • [Cites] Mol Cell. 2008 Sep 26;31(6):918-24 [18922473.001]
  • [Cites] Carcinogenesis. 2008 Nov;29(11):2227-35 [18725385.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):466-74 [19147559.001]
  • [Cites] J Clin Invest. 2009 Feb;119(2):252-66 [19147981.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10290-5 [19502425.001]
  • [Cites] Nat Med. 2009 Aug;15(8):960-6 [19597504.001]
  • [Cites] Oncogene. 2001 May 10;20(21):2626-35 [11420674.001]
  • (PMID = 19740433.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA129359; United States / NCI NIH HHS / CA / CA129359
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; 0 / Indoles; 0 / Integrin beta3; 0 / N-methyl-N-(3-((2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino)-methyl)-pyridin-2-yl)-methanesulfonamide; 0 / Quinolones; 0 / RNA, Small Interfering; 0 / Receptors, Transforming Growth Factor beta; 0 / Sulfonamides; 0 / Sulfones; 0 / Transforming Growth Factor beta; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  • [Other-IDs] NLM/ PMC2790843
  •  go-up   go-down


5. Alexopoulou A, Koskinas J, Deutsch M, Delladetsima J, Kountouras D, Dourakis SP: Acute liver failure as the initial manifestation of hepatic infiltration by a solid tumor: report of 5 cases and review of the literature. Tumori; 2006 Jul-Aug;92(4):354-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute liver failure as the initial manifestation of hepatic infiltration by a solid tumor: report of 5 cases and review of the literature.
  • Recognition of malignant infiltration of the liver as the cause of acute liver failure could be a diagnostic challenge.
  • Liver imaging studies in 2 of the 5 patients were nondiagnostic and the malignant liver infiltration was confirmed postmortem.
  • Liver histology in all cases showed massive tumoral infiltration of the hepatic sinusoids with diffuse replacement of hepatocytes.
  • The primary tumors were colon, gastric, small cell lung, pancreas and cancer of unknown origin.
  • CONCLUSIONS: Malignant infiltration of the liver should be taken into account in the differential diagnosis of rapidly progressive liver failure.
  • Although effective chemotherapy has improved the survival of patients with metastatic liver disease, there has been no change in the course and outcome of acute liver failure due to malignant infiltration of the liver over the last 2 decades.
  • [MeSH-minor] Adult. Aged, 80 and over. Biopsy. Female. Hepatic Encephalopathy / etiology. Humans. Jaundice / etiology. Liver Function Tests. Lung Neoplasms / pathology. Male. Medical Records. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036530.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


6. Donthireddy KR, Ailawadhi S, Nasser E, Schiff MD, Nwogu CE, Nava HR, Javle MM: Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol; 2007 Sep;5(8):355-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant gastroparesis: pathogenesis and management of an underrecognized disorder.
  • Gastroparesis has been described as a complication of several malignancies, including gastric, pancreatic, gallbladder, esophageal, and lung cancers, as well as leiomyosarcoma.
  • The prevalence of malignant gastroparesis (MG) is unknown, and this entity is widely underrecognized and undertreated.
  • Diabetes mellitus is the most common identifiable cause of benign gastroparesis, ie, gastroparesis occurring in the absence of an underlying malignant pathology.
  • In the setting of malignancy, gastroparesis may result from the cancer itself or may be a complication of its treatment with such modalities as surgery, radiation therapy, or chemotherapy.
  • However, mechanisms suggested in the literature include postvagotomy syndrome, malignant infiltration of the autonomic nervous system, and paraneoplastic dysmotility with autoantibody-mediated destruction of the enteric nervous system (the interstitial cells of Cajal, also called the intrinsic pacemaker of the gastrointestinal tract, or the myenteric plexus).
  • Appropriate treatment of MG may help to avoid serious consequences, such as cancer cachexia, intolerance of oral anticancer agents, dehydration, and hospitalization.
  • [MeSH-major] Gastric Emptying. Gastrointestinal Agents / therapeutic use. Gastrointestinal Motility / drug effects. Gastroparesis / etiology. Neoplasms / complications
  • [MeSH-minor] Cathartics / therapeutic use. Humans. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Gastroparesis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Support Oncol. 2007 Sep;5(8):368-70 [17944145.001]
  • [CommentIn] J Support Oncol. 2007 Sep;5(8):366-7 [17944144.001]
  • (PMID = 17944143.001).
  • [ISSN] 1544-6794
  • [Journal-full-title] The journal of supportive oncology
  • [ISO-abbreviation] J Support Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cathartics; 0 / Gastrointestinal Agents
  • [Number-of-references] 52
  •  go-up   go-down


7. Radulescu D, Pripon S, Ciuleanu TE, Radulescu LI: Malignant primary pulmonary tumor with hemangiopericytoma-like features: conventional hemangiopericytoma versus solitary fibrous tumor. Clin Lung Cancer; 2007 Sep;8(8):504-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant primary pulmonary tumor with hemangiopericytoma-like features: conventional hemangiopericytoma versus solitary fibrous tumor.
  • Although extremely rare, the primitive lung hemangiopericytoma in adults is similar to hemangiopericytomas with other soft tissue localizations.
  • Although generally benign and curable after radical surgery, it might also have a malignant clinical course with dissemination in both lungs, infiltration of vital organs (heart, pulmonary artery), extension to the adjacent tissues, and even pulmonary metastases.
  • The treatment of choice is the complete tumor resection with negative surgical margins after excision.
  • Certain histologic features might indicate a malignant potential.
  • The clinical outcome of patients is variable: some are cured after radical surgery and others might present relapse and recurrences that necessitate a second intervention, radiation therapy, and/or chemotherapy.
  • Over the years, the conventionally-defined hemangiopericytoma concept has evolved because of the nonspecific histologic growth pattern (characteristic monotonous appearance, moderate or high cellularity, and a well-developed branching vascular pattern) shared by numerous, unrelated benign or malignant lesions.
  • We report an uncommon case of primitive lung tumor exhibiting hemangiopericytoma-like features, with an aggressive, fatal clinical course.
  • Because of the major histologic overlap between solitary fibrous tumor and hemangiopericytoma and lack of clear classification criteria, we encountered difficulty in including this case in a known clinical entity; primitive solitary fibrous tumor of the lung, which mimics lung hemangiopericytoma, seemed to be the most plausible diagnosis.
  • [MeSH-major] Hemangiopericytoma / pathology. Lung Neoplasms / pathology. Solitary Fibrous Tumors / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922977.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Lachat MR, Weber M, Cserhati MD, Honegger HP, von Hochstetter AR: [Giant cell tumor of bone with rapid malignant course]. Orthopade; 2004 Mar;33(3):344-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant cell tumor of bone with rapid malignant course].
  • [Transliterated title] Riesenzelltumor des Knochens mit rapid malignem Verlauf.
  • The case of a 28-year-old male patient with a locally aggressive lesion of the distal tibia is presented.
  • Following the diagnosis of giant cell tumor of bone (GCT) on biopsy and curettage, a rapid malignant course was observed with recurrence 2.5 months later.
  • Following initial chemotherapy according to the COSS protocol and later with carboplatin and VP-16, therapy was changed to Adriamycin and later gemcitabine due to progressive disease.
  • The malignant nature of the tumor was not detected in the initial pathologic examinations.
  • Review of the pathologic material provided histologic clues permitting the diagnosis of a primary malignant GCT with a fibrohistiocytic/fibrosarcomatous component.
  • Cytologic atypias and flame-like tufts of infiltration of soft tissue are important clues.
  • Surgical treatment should be commensurate.
  • [MeSH-major] Ankle Joint. Bone Neoplasms / diagnosis. Giant Cell Tumor of Bone / secondary. Lung Neoplasms / secondary. Tibia
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Bone Transplantation. Curettage. Disease Progression. Fatal Outcome. Humans. Lung / pathology. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Reoperation. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1985 Jul;67(6):890-900 [4019539.001]
  • [Cites] J Bone Joint Surg Am. 1987 Jan;69(1):106-14 [3805057.001]
  • [Cites] Cancer. 1985 Mar 15;55(6):1244-55 [3855683.001]
  • [Cites] J Bone Joint Surg Br. 1998 Jan;80(1):43-7 [9460951.001]
  • [Cites] J Bone Joint Surg Am. 1986 Sep;68(7):1073-9 [3745247.001]
  • [Cites] Skeletal Radiol. 2001 Feb;30(2):104-8 [11310196.001]
  • [Cites] J Bone Joint Surg Am. 1997 Feb;79(2):259-62 [9052550.001]
  • [Cites] Mod Pathol. 1989 Sep;2(5):541-6 [2554283.001]
  • [Cites] Cancer. 1979 Oct;44(4):1393-402 [227563.001]
  • [Cites] J Bone Joint Surg Am. 1992 Jul;74(6):930-4 [1634584.001]
  • [Cites] J Bone Joint Surg Am. 1989 Jun;71(5):757-61 [2732265.001]
  • [Cites] Clin Orthop Relat Res. 2000 Dec;(381):185-91 [11127655.001]
  • [Cites] J Bone Joint Surg Br. 1972 May;54(2):216-29 [5034822.001]
  • [Cites] Skeletal Radiol. 1997 Apr;26(4):246-55 [9151375.001]
  • [Cites] AJR Am J Roentgenol. 1985 May;144(5):955-60 [3872579.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1641-9 [7417958.001]
  • (PMID = 15007559.001).
  • [ISSN] 0085-4530
  • [Journal-full-title] Der Orthopade
  • [ISO-abbreviation] Orthopade
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Martin AC, Friedlander M, Kiernan MC: Paraneoplastic mononeuritis multiplex in non-small-cell lung carcinoma. J Clin Neurosci; 2006 Jun;13(5):595-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic mononeuritis multiplex in non-small-cell lung carcinoma.
  • A 60-year-old man developed two selective peripheral mononeuropathies of the peroneal and later the radial nerve, shortly after a diagnosis of large-cell lung carcinoma.
  • Subsequent magnetic resonance imaging of the lower limb excluded focal compression or malignant infiltration along the course of the peroneal nerve, and there was no signal change within the nerve, prompting a diagnosis of paraneoplastic mononeuritis multiplex.
  • Neither the patient's large-cell lung carcinoma nor mononeuritis multiplex responded to chemotherapy, and he died within 6 months of the initial diagnosis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiography. Paraneoplastic Polyneuropathy / radiography. Peroneal Neuropathies / radiography. Radial Neuropathy / radiography

  • Genetic Alliance. consumer health - Mononeuritis multiplex.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564174.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


10. Xia R, Chen X: Effects of Danshen injection on the malignant obstructive jaundice in the SD rat model. J Huazhong Univ Sci Technolog Med Sci; 2006;26(6):686-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of Danshen injection on the malignant obstructive jaundice in the SD rat model.
  • To observe the effects of Danshen on the growth of hepatocellular carcinoma in the SD rats, a model of malignant obstructive jaundice was established by inoculation of transplanted tumor into the hepatic portal with the walker-256 hepatocarcinoma line, which resulted in the obstruction by the infiltration and metastasis of hepatocellular carcinoma.
  • The liver function, morphological changes and the expressions of PCNA, VEGF and ICAM-1 in carcinoma foci, peri-carcinoma tissues, adjacent lobe (left-internal lobe) and lung tissues were observed after the treatment with the 4 agents.
  • The expressions of PCNA,VEGF and ICAM-1 PCNA, VEGF and ICAM-1 in carcinoma foci, peri-carcinoma tissues, adjacent lobe (left-internal lobe) and lung tissues were lower than those in control group and InV group, with the differences being significant (P<0.01).
  • [MeSH-major] Drugs, Chinese Herbal / therapeutic use. Jaundice, Obstructive / drug therapy. Phenanthrolines / therapeutic use

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ai Zheng. 2003 Dec;22(12):1363-6 [14693071.001]
  • (PMID = 17357489.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Phenanthrolines; 0 / Proliferating Cell Nuclear Antigen; 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, rat; 126547-89-5 / Intercellular Adhesion Molecule-1; 79483-68-4 / dan-shen root extract
  •  go-up   go-down


11. Koschmieder S, Fauth F, Kriener S, Hoelzer D, Seipelt G: Effective treatment of simultaneous small cell lung cancer and B-cell lymphoma. Leuk Lymphoma; 2002 Mar;43(3):645-7
Genetic Alliance. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of simultaneous small cell lung cancer and B-cell lymphoma.
  • Malignant lymphomas have been reported previously to coincide with adenocarcinomas of the stomach and, rarely, the kidney, breast, colon, liver, or lung.
  • Here, we describe the first case to our knowledge of a malignant lymphoma and an extensive disease small cell cancer of the lung.
  • Further staging revealed a dense infiltration of the bone marrow by both a small cell lung cancer and a malignant lymphoma.
  • Both tumors responded well to chemotherapy.
  • This unique case report demonstrates that the simultaneous occurrence of small cell lung cancers and malignant lymphomas is extremely rare and may effectively be treated with chemotherapy.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow / pathology. Humans. Liver / pathology. Male. Middle Aged. Neoplasm Invasiveness. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12002773.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


12. Krieghoff B, Skuballa A, Leonhardt P, Mohr FW, Wittekind C, Bossert T, Achatzy R: [Primary synovial sarcoma of the lung - a rare tumor]. Zentralbl Chir; 2002 Aug;127(8):716-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary synovial sarcoma of the lung - a rare tumor].
  • We present a 26 year old patient with a primary malignant synovial sarcoma of the lung that was observed for more than one year by a general practitioner and a pulmologist.
  • In the postoperative course the patient underwent chemo-therapy, 6 cycles adriablastine/ifosfamid.
  • 8 months after the first operation an extensive tumor recurrency occurred with infiltration of the chest wall.
  • The patient refused further radio- or chemotherapy and died 14 months after the operation.
  • Because of the small number of cases therapeutic strategy conceptions do not exist.
  • [MeSH-major] Lung Neoplasms / surgery. Sarcoma, Synovial / surgery
  • [MeSH-minor] Adult. Bronchoscopy. Diagnosis, Differential. Diagnostic Imaging. Humans. Lung / pathology. Male. Neoplasm Staging. Pneumonectomy

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12200737.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Woźniak AW, Nowaczyk MT, Osmola K, Golusinski W: Malignant transformation of an osteoblastoma of the mandible: case report and review of the literature. Eur Arch Otorhinolaryngol; 2010 Jun;267(6):845-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of an osteoblastoma of the mandible: case report and review of the literature.
  • Postoperative recurrence with soft tissue infiltration suggested an osteosarcoma radiologically, but the histological examination again revealed the presence of an osteoblastoma.
  • A second recurrence occured in the pharyngo-glossal region and this time the tumor was histologically diagnosed as an osteoblastoma, but with foci of well-differentiated osteosarcoma.
  • The patient was given a course of radiotherapy, but clinical and radiological examination 8 months later revealed lung metastases and chemotherapy was started.
  • While osteoblastomas are rare, and their sarcomatous change even rarer, our experience with this case lead us to suggest that a therapeutic preventative approach, involving both chemotherapy and total excision of the tumor, is the regime to adopt with osteoblastomas which involve soft tissues and have radiological features suggesting malignancy.
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Male. Mandible / pathology. Mandible / surgery. Radiography, Panoramic. Radiotherapy, Adjuvant. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Spine J. 1998;7(3):246-8 [9684960.001]
  • [Cites] J Clin Pathol. 1993 Nov;46(11):1024-9 [8254089.001]
  • [Cites] Neurosurg Rev. 1997;20(1):51-4 [9085288.001]
  • [Cites] Histopathology. 1997 Aug;31(2):196-200 [9279574.001]
  • [Cites] Med Pediatr Oncol. 1997 Apr;28(4):305-9 [9078333.001]
  • [Cites] Skeletal Radiol. 1994 Oct;23 (7):509-12 [7824976.001]
  • [Cites] J Neurosurg. 1991 Jul;75(1):138-42 [2045899.001]
  • [Cites] Gen Diagn Pathol. 1996 May;141(5-6):377-92 [8780939.001]
  • [Cites] Eur J Radiol. 1998 May;27 Suppl 1:S91-7 [9652508.001]
  • [Cites] Skeletal Radiol. 1994 Nov;23 (8):656-9 [7886478.001]
  • [Cites] Aktuelle Radiol. 1996 Nov;6(6):338-40 [9081408.001]
  • [Cites] Cancer. 1985 Jan 15;55(2):416-26 [3855268.001]
  • [Cites] J Comput Assist Tomogr. 1996 Jan-Feb;20(1):116-8 [8576460.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):117-34 [8119712.001]
  • [Cites] Chirurg. 2002 Dec;73(12 ):1181-90 [12491047.001]
  • [Cites] Arq Neuropsiquiatr. 1998 Jun;56(2):292-5 [9698743.001]
  • [Cites] J Laryngol Otol. 1997 Sep;111(9):865-8 [9373556.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Jan;52(1):86-90 [8263651.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Feb;18(2):324-6 [9111670.001]
  • [Cites] Surg Neurol. 1998 Mar;49(3):274-7 [9508114.001]
  • (PMID = 20012077.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 20
  •  go-up   go-down


14. Kobayashi K, Yano S, Kato K, Morita M, Tatsukawa T, Ikeda T, Tokushima T: [A case of M. fortuitum lung disease with small-cell lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2004 May;42(5):424-8
Hazardous Substances Data Bank. MINOCYCLINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of M. fortuitum lung disease with small-cell lung cancer].
  • Chest radiographs and chest CT on admission showed a bulla with a niveau and infiltration in the right upper lobe.
  • Despite treatment with meropenem and clindamycin, the infiltrating shadow worsened.
  • Since bronchial lavage and sputum culture were positive for M. fortuitum, these drugs were replaced with minocycline and imipenem.
  • After discharge, outpatient treatment with clarithromycin and levofloxacin was continued.
  • When a CT-guided transcutaneous needle lung biopsy was undertaken, malignant cells were found.
  • Pathological examination of the lesion demonstrated small-cell lung cancer.
  • If a lesion does not change after nontuberculous mycobacteria treatment, the physician should consider other lesions such as lung cancer.
  • [MeSH-major] Carcinoma, Small Cell / etiology. Lung Neoplasms / etiology. Mycobacterium Infections, Nontuberculous / drug therapy. Mycobacterium fortuitum. Tuberculosis, Pulmonary / drug therapy
  • [MeSH-minor] Anti-Bacterial Agents / administration & dosage. Cilastatin / administration & dosage. Drug Combinations. Humans. Imipenem / administration & dosage. Male. Middle Aged. Minocycline / administration & dosage. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15168461.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Drug Combinations; 141A6AMN38 / Cilastatin; 71OTZ9ZE0A / Imipenem; 92309-29-0 / cilastatin, imipenem drug combination; FYY3R43WGO / Minocycline
  •  go-up   go-down


15. Kalac M, Ostojić S, Gasparov S, Planinc-Peraica A, Dominis M, Jaksić B: [Microcellular lung carcinoma in patient with hepatosplenic T-cell lymphoma: a case report]. Lijec Vjesn; 2006 Mar-Apr;128(3-4):76-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Microcellular lung carcinoma in patient with hepatosplenic T-cell lymphoma: a case report].
  • Hepatosplenic T-cell lymphoma (HSTCL) is a rare form of extranodal non-Hodgkin lymphoma derived from cytotoxic T-cells, usually manifesting by sinusoidal infiltration of spleen, liver and bone marrow.
  • In 1997 World Health Organization classified malignant lymphomas and placed HSTCL among peripheral T-cell neoplasms.
  • The course of the diseases is usually very agressive with a median survival time of 8 to 16 moths despite multiagent chemotherapy.
  • As a first line of lymphoma therapy we decided to apply FED course (fludarabine, cyclophosphamide, prednisone), being aware of the published poor results the standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisolone) yields.
  • As far as we know, the results of this chemotherapy course in the therapy of this tumor have never been published.
  • The patient underwent 6 courses of FED therapy, which he tolerated well and was in good clinical condition.
  • Upon the completion of the 6th course of therapy he was diagnosed with lung anaplastic microcellular carcinoma and was treated with 3 course of PE therapy (cisplatin, etoposide).
  • [MeSH-major] Carcinoma, Small Cell / pathology. Liver Neoplasms / pathology. Lung Neoplasms / pathology. Lymphoma, T-Cell / pathology. Neoplasms, Second Primary / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16808095.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


16. Miura H, Kitamura S, Yamada H: An autopsy case of autoimmune pancreatitis after a 6-year history of steroid therapy accompanied by malignant dissemination of unknown origin. Eur J Gastroenterol Hepatol; 2008 Sep;20(9):930-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An autopsy case of autoimmune pancreatitis after a 6-year history of steroid therapy accompanied by malignant dissemination of unknown origin.
  • Little is known about the long-term outcome of autoimmune pancreatitis (AIP), and whether AIP possesses malignant potential.
  • We report herein a 68-year-old Japanese AIP patient who rapidly developed systemic malignant dissemination of unknown origin, resulting in death.
  • After a 6-year history of 5 mg/day of prednisolone therapy, a sudden onset of abdominal pain and convulsive seizure occurred, and the patient died on the tenth hospital day owing to diffuse peritoneal disseminations and metastases in the bilateral lungs and brain.
  • On microscopy, metastatic cells obtained from the brain, lung, and peritoneum were composed of pleomorphic malignant cells identical to those from the renal cell carcinoma.
  • Unexpectedly, abundant IgG4-positive plasma cell infiltration, suggesting high activity of AIP in pancreatic parenchyma and around dilated bile ducts, was still observed.
  • [MeSH-major] Autoimmune Diseases / drug therapy. Carcinoma, Renal Cell / secondary. Glucocorticoids / adverse effects. Pancreatitis, Chronic / drug therapy. Prednisolone / adverse effects
  • [MeSH-minor] Disease Progression. Fatal Outcome. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794609.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


17. Koyama S, Sato E, Takamizawa A, Tsukadaira A, Haniuda M, Kurai M, Numanami H, Nagai S, Izumi T: Methotrexate stimulates lung epithelial cells to release inflammatory cell chemotactic activities. Exp Lung Res; 2003 Mar;29(2):91-111
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methotrexate stimulates lung epithelial cells to release inflammatory cell chemotactic activities.
  • Methotrexate-induced pneumonitis has been reported as an infrequent but potentially serious complication of therapy in a variety of malignant and benign conditions.
  • Because inflammatory cell infiltration is concerned with the development of methotrexate-induced pneumoinitis, and because airway epithelial cells participate in the orchestration of lung inflammation, the authors determined whether methotrexate might stimulate airway epithelial cells (A549 cells) to release neutrophil, monocyte, and eosinophil chemotactic activities (NCA, MCA, and ECA).
  • A549 cells released NCA, MCA, and ECA in a dose- and time-dependent manner in response to methotrexate.
  • These data suggest that type II epithelial cells may modulate inflammatory cell recruitment into the lung by releasing NCA, MCA, and ECA in response to methotrexate.
  • [MeSH-major] Antimetabolites, Antineoplastic / toxicity. Chemokines / secretion. Epithelial Cells / drug effects. Methotrexate / pharmacology. Pulmonary Alveoli / drug effects
  • [MeSH-minor] Antibodies, Blocking / pharmacology. Dose-Response Relationship, Drug. Enzyme Inhibitors / pharmacology. Humans. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12554356.001).
  • [ISSN] 0190-2148
  • [Journal-full-title] Experimental lung research
  • [ISO-abbreviation] Exp. Lung Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Blocking; 0 / Antimetabolites, Antineoplastic; 0 / Chemokines; 0 / Enzyme Inhibitors; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


18. Tabarkiewicz J, Rybojad P, Jablonka A, Rolinski J: CD1c+ and CD303+ dendritic cells in peripheral blood, lymph nodes and tumor tissue of patients with non-small cell lung cancer. Oncol Rep; 2008 Jan;19(1):237-43
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD1c+ and CD303+ dendritic cells in peripheral blood, lymph nodes and tumor tissue of patients with non-small cell lung cancer.
  • Dendritic cells (DCs) are the most potent antigen presenting cells, which can stimulate a cellular immune response against malignant tumor cells.
  • Many authors have described the phenomenon of tumor infiltration by dendritic cells and emphasized an immunosuppressive tumor influence on DC function.
  • In the present study, we examined the presence of myeloid CD1c+ (BDCA-1+) dendritic cells and lymphoid/plasmacytoid CD303+ (BDCA-2+) dendritic cells in peripheral blood, lymph nodes and cancer tissue of patients with non-small cell lung cancer (NSCLC).
  • Fifty male patients treated surgically for NSCLC stages I-IIIa without neoadjuvant chemotherapy were included.
  • Employing a multiparameter flow cytometry for CD1c, CD19, CD123 and CD303, we observed an accumulation of immature DCs in the tissues involved in the neoplasmatic process with the predominance of lymphoid/plasmacytoid over myeloid DCs.
  • [MeSH-major] Antigens, CD1 / metabolism. Carcinoma, Non-Small-Cell Lung / immunology. Dendritic Cells / metabolism. Glycoproteins / metabolism. Lectins, C-Type / metabolism. Lung Neoplasms / immunology. Membrane Glycoproteins / metabolism. Receptors, Immunologic / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097601.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD1; 0 / CD1C protein, human; 0 / CLEC4C protein, human; 0 / Glycoproteins; 0 / Lectins, C-Type; 0 / Membrane Glycoproteins; 0 / Receptors, Immunologic
  •  go-up   go-down


19. Bednaríková M, Valík D, Vyzula R: [Somatostatin analogues in the treatment of carcinoid]. Cas Lek Cesk; 2008;147(4):233-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Somatostatin analogues in the treatment of carcinoid].
  • The patient--born in 1960, was first diagnosed in 1981 as having malignant carcinoid of the right lung.
  • According to tumor histology--atypical carcinoid--this patient was initially treated with palliative systemic chemotherapy, specifically with cisplatin and etoposid.
  • His disease stabilized after administration of 4 cycles of chemotherapy.
  • The treatment was accompanied by protracted toxicity with marked alteration of his general conditions after the 4th cycle.
  • The symptoms disappeared, except a persisting ocular disorder due to periorbital infiltration.
  • This case study illustrates the necessity of cautious and individual approach to the choice of treatment strategy in patients with malignant carcinoid.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoid Tumor / drug therapy. Lung Neoplasms / pathology. Somatostatin / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18578378.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 51110-01-1 / Somatostatin
  •  go-up   go-down


20. Pentheroudakis G, Pavlidis N: Management of leptomeningeal malignancy. Expert Opin Pharmacother; 2005 Jun;6(7):1115-25
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leptomeningeal carcinomatosis is defined as malignant infiltration of the pia matter and arachnoid membrane.
  • Leukaemias and lymphomas, lung, breast cancer and melanoma are the primary tumours commonly associated with leptomeningeal carcinomatosis.
  • Treatment is largely palliative (median survival 2-4 months).
  • Available treatment options include focal radiation therapy to CNS sites of bulky, symptomatic or obstructive meningeal deposits, intrathecal cytotoxic therapy and systemic chemotherapy.
  • No evidence of superiority of intrathecal treatment compared with best palliative care (including radiation therapy and systemic treatment) is available from clinical trials.
  • Novel treatment approaches include intrathecal liposomal Ara-C, the development of new cytotoxic compounds, signal transduction inhibitors and monoclonal antibodies for intrathecal or systemic use.
  • Until data from multi-centre randomised trials are available, rationalisation of therapy should be done by stratifying patients to prognostic groups.
  • High-risk patients will only survive for a few weeks and are better managed with supportive measures, whereas low-risk patients justify vigorous cerebrospinal fluid-directed treatment combined with radiation therapy and systemic chemotherapy.
  • [MeSH-major] Arachnoid Cysts / drug therapy. Carcinoma / drug therapy. Meningeal Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / pathology. Algorithms. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / cerebrospinal fluid. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / cerebrospinal fluid. Antineoplastic Agents, Alkylating / therapeutic use. Combined Modality Therapy. Cranial Irradiation. Cytarabine / administration & dosage. Cytarabine / cerebrospinal fluid. Cytarabine / therapeutic use. Delayed-Action Preparations. Enzyme Inhibitors / therapeutic use. Humans. Injections, Intravenous. Injections, Spinal. Leukemia / pathology. Lymphoma / pathology. Methotrexate / administration & dosage. Methotrexate / cerebrospinal fluid. Methotrexate / therapeutic use. Palliative Care. Randomized Controlled Trials as Topic. Thiotepa / administration & dosage. Thiotepa / cerebrospinal fluid. Thiotepa / therapeutic use. Topoisomerase I Inhibitors. Topotecan / therapeutic use

  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15957966.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Delayed-Action Preparations; 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 04079A1RDZ / Cytarabine; 7M7YKX2N15 / Topotecan; 905Z5W3GKH / Thiotepa; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 43
  •  go-up   go-down


21. Christiansen S, Semik M, Dockhorn-Dworniczak B, Rötker J, Thomas M, Schmidt C, Jürgens H, Winkelmann W, Scheld HH: Diagnosis, treatment and outcome of patients with Askin-tumors. Thorac Cardiovasc Surg; 2000 Oct;48(5):311-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis, treatment and outcome of patients with Askin-tumors.
  • Askin tumors are highly malignant small-round-cell tumors of the thoracopulmonary region, which occur rarely.
  • In all patients, the tumor arose from the chest wall, infiltrating adjacent ribs and parts of the lung.
  • At the time of first diagnosis, five patients did not reveal any metastases.
  • One patient suffered from intrapulmonary metastases and two patients from an infiltration of the diaphragm and of adjacent vertebral bodies.
  • Treatment consisted of a pre- and postoperative (radio-) chemotherapy according to the EVAIA protocol and a radical tumor resection in all patients.
  • Our data demonstrate that Askin tumors require an aggressive multimodality treatment consisting of pre- and postoperative chemotherapy, radical surgical resection and postoperative irradiation, which may be performed preoperatively in selected cases, too.
  • [MeSH-major] Lung Neoplasms. Sarcoma, Small Cell. Thoracic Neoplasms
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Female. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11100769.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] GERMANY
  • [Number-of-references] 17
  •  go-up   go-down


22. Klenke FM, Merkle T, Fellenberg J, Abdollahi A, Huber PE, Gebhard MM, Ewerbeck V, Sckell A: A novel model for the investigation of orthotopically growing primary and secondary bone tumours using intravital microscopy. Lab Anim; 2005 Oct;39(4):377-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here is reported the development of an experimental model using intravital microscopy as a tool to orthotopically investigate malignant bone tumours.
  • Although up to 85% of the most frequently occurring malignant solid tumours, such as lung and prostate carcinomas, metastasize into the bone, and despite the knowledge that a tumour's course may be altered by its surrounding tissue, there is no adequate experimental model available enabling the investigation of orthotopically grown bone tumours in vivo.
  • Intravital microscopy is an internationally accepted experimental method, used in various acute and chronic animal models, that enables qualitative and quantitative analysis of the angiogenesis, microcirculation, growth behaviour, etc. of various benign and malignant tissues.
  • Additionally, tissue samples can be taken after termination of the in vivo experiments for further ex vivo investigation (histology, immunohistochemistry, molecular biology, etc.
  • Severe combined immunodeficient mice were fitted with a cranial window preparation where the calvaria served as the site for orthotopic implantation of the solid human tumours Saos-2 osteosarcoma (primary) and A 549 lung carcinoma and PC-3 prostate carcinoma (secondary).
  • Histological assessment confirmed the data obtained in vivo, showing typical tumour growth with infiltration of the surrounding osseous and soft tissues.
  • This novel model serves as a valuable tool in understanding the biology of primary and secondary bone tumours in physiological and pathophysiological situations, with implications for the most areas of tumour therapy such as chemotherapy, radiation and antiangiogenesis.
  • [MeSH-minor] Animals. Lung Neoplasms / pathology. Male. Mice. Mice, SCID. Microscopy, Fluorescence. Microscopy, Video. Neoplasm Transplantation. Neovascularization, Pathologic / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197704.001).
  • [ISSN] 0023-6772
  • [Journal-full-title] Laboratory animals
  • [ISO-abbreviation] Lab. Anim.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


23. Tateishi T, Tanaka K, Ito Y, Mitsuo K: [Case of X-linked lymphoproliferative syndrome (XLP) with multiple nodular lesions in the brain]. Rinsho Shinkeigaku; 2006 Apr;46(4):254-60
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He developed agammaglobulinemia following Epstein-Barr virus infection at 3-year-old, and thereafter was administered 7.5g of immunoglobulin every 3 weeks with a diagnosis of XLP.
  • Neurological examination revealed disorientation of time, and bilateral gaze-evoked nystagmus.
  • The needle lung biopsy was performed, which showed infiltration of lymphocytes around the vessels.
  • The histological findings excluded intravascular malignant lymphoma and lymphomatoid granulomatosis.
  • The patient developed pancytopenia caused by hemophagocytic syndrome 48 days after admission and was treated with 1 g of methylprednisolone per day for 3 days and a tapered dose of steroid (500 mg to 125 mg of methylprednisolone and 60 mg to 10mg of predonisolone) for 21 days, which resulted in the improvement of clinical features (hemophagocytic syndrome and central nervous system symptoms) and the abnormal CSF findings.
  • The multple nodular lesions in the brain and the lungs shrank 1 month after treatment and disappeared 11 months later.
  • There are few reports concerning lymphoid vasculitis with XLP, and no effective treatment has been described.
  • Our case suggests that steroid therapy may be useful for the treatment of lymphoid vasculitis in XLP.
  • [MeSH-minor] Adult. Brain / pathology. Humans. Lung / pathology. Lung / radiography. Lymphohistiocytosis, Hemophagocytic / drug therapy. Lymphohistiocytosis, Hemophagocytic / etiology. Magnetic Resonance Imaging. Male. Methylprednisolone / administration & dosage. Prednisolone / administration & dosage. Pulse Therapy, Drug. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoproliferative syndrome X-linked 1.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16768091.001).
  • [ISSN] 0009-918X
  • [Journal-full-title] Rinshō shinkeigaku = Clinical neurology
  • [ISO-abbreviation] Rinsho Shinkeigaku
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9PHQ9Y1OLM / Prednisolone; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


24. Yamazaki Y, Fujiuchi S, Matsumoto H, Takahashi T, Takeda A, Fujita Y, Fujikane T, Shimizu T, Nishigaki Y: [Two cases of pulmonary Mycobacterium xenopi infection]. Nihon Kokyuki Gakkai Zasshi; 2003 Aug;41(8):556-60
Genetic Alliance. consumer health - Mycobacterium Xenopi.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • His chest radiograph revealed a cavitary lesion with a granular shadow in the right upper lung field.
  • His sputum and bronchial lavage were negative for acid-fast bacilli and malignant cells.
  • For a definitive diagnosis, lung resection was performed by video-assisted thoracoscopy.
  • His chest radiograph showed a cavitary lesion with infiltration in the right upper lung field.
  • Despite medication with isoniazide, rifampicin and ethambutol, the infiltrative shadow in his radiograph increased in size.
  • It is necessary to consider carefully whether surgical resection is required when chemotherapy is refused by the patient or is likely to be unsuccessful.
  • [MeSH-major] Mycobacterium Infections, Nontuberculous / diagnosis. Mycobacterium Infections, Nontuberculous / therapy. Mycobacterium xenopi. Tuberculosis, Pulmonary / diagnosis
  • [MeSH-minor] Adult. Antitubercular Agents / therapeutic use. Humans. Male. Middle Aged. Pneumonectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14503343.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


25. Gundling F, Zillinger C, Schmidt T, Ingrisch H, Heitland W, Nerlich A, Schepp W: [A 67-year-old patient with diarrhoea and constipation without any pathological findings in virtual colonoscopy]. Z Gastroenterol; 2005 May;43(5):455-9
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] 67-jähriger Patient mit paradoxer Diarrhoe und unauffälliger virtueller Koloskopie.
  • However, conventional video-colonoscopy revealed a subtotal circular malignant stenosis in the region of the right colonic flexure.
  • Staging showed peritoneal carcinosis with infiltration of the right ureter and lymphangiosis carcinomatosa of the pectoral lobe of the left lung.
  • After right hemicolectomy because of metastasised carcinoma of the ascending colon (pT4pN1pM1) we started palliative chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin.


26. Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Körholz D, Pape H, Dunst J, Kahn T, Willers R, Engel B, Dirksen U, Kramm C, Nürnberger W, Heyll A, Ladenstein R, Gadner H, Jürgens H, Go el U: Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol; 2000 Nov;11(11):1451-62
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to evaluate a possible therapeutic benefit after allogeneic SCT in patients with advanced Ewing tumors (AET), we compared outcome after autologous and allogeneic stem-cell transplantation (SCT).
  • All patients underwent remission induction chemotherapy and local treatment before myeloablative therapy.
  • We analyzed the following risk factors, that could possibly influence the event-free survival (EFS): number of involved bones, degree of remission at time of SCT, type of graft, indication for SCT, bone marrow infiltration, bone with concomitant lung disease, age at time of diagnosis, pelvic involvement, involved compartment radiation, histopathological diagnosis.
  • Eighteen of thirty-six patients suffered relapse or died of disease, nine of thirty-six died of treatment related toxicity (DOC).
  • According to the type of graft, EFS was 0.25 +/- 0.08 after autologous and 0.20 +/- 0.13 after allogeneic SCT.
  • CONCLUSIONS: Because of the rather short observation period. secondary malignant neoplasms (SMN) may complicate the future clinical course of some of our patients who are currently viewed as event-free survivors.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11142486.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Interleukin-2
  • [Number-of-references] 56
  •  go-up   go-down


27. Kittan NA, Hildebrandt GC: The chemokine system: a possible therapeutic target in acute graft versus host disease. Curr Top Microbiol Immunol; 2010;341:97-120

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The chemokine system: a possible therapeutic target in acute graft versus host disease.
  • Allogeneic hematopoetic stem cell transplantation often presents the only chance for cure in a number of malignant and nonmalignant hematologic diseases.
  • Alloantigen-reactive immune responses mediate injury and destruction of GVHD target organs, including the gastrointestinal tract, the liver, the skin, and the lung.
  • Donor leukocyte infiltration into the respective tissues is orchestrated by interactions between chemokines and chemokine receptors, which will be reviewed using a basic science - clinical comparative approach.
  • [MeSH-major] Chemokines / antagonists & inhibitors. Graft vs Host Disease / drug therapy. Graft vs Host Disease / immunology. Receptors, Chemokine / antagonists & inhibitors
  • [MeSH-minor] Animals. Hematologic Diseases / therapy. Hematopoietic Stem Cell Transplantation / adverse effects. Humans. Signal Transduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379809.001).
  • [ISSN] 0070-217X
  • [Journal-full-title] Current topics in microbiology and immunology
  • [ISO-abbreviation] Curr. Top. Microbiol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chemokines; 0 / Receptors, Chemokine
  •  go-up   go-down


28. Fong D, Steurer M, Greil R, Gunsilius E, Spizzo G, Gastl G, Tzankov A: Hodgkin lymphoma in Tyrol-a population-based study. Ann Hematol; 2009 May;88(5):449-56
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Age (p < 0.01), sex (p = 0.03), risk groups according to the German Hodgkin Study Group stratification (p < 0.01), and bone marrow infiltration (p < 0.01) were of prognostic significance considering overall survival (OS) whereas histological subtype and bulky disease were not.
  • Notably, in patients with advanced-stage HL (n = 49), combined modality treatment resulted in significantly better OS than chemotherapy alone (p = 0.01).
  • Three patients developed a second hematological malignancy and one patient developed breast cancer.
  • However, five patients (3%) had a malignant hematological disorder before occurrence of HL.
  • Concerning treatment-related toxicity, bleomycin-associated lung toxicity was observed in six (4%) patients and five (3%) developed lethal treatment-related infectious complications.
  • Modern risk-adapted treatment results in excellent long-term prognosis but may be complicated by serious nonhematological side effects, in particular, infections and bleomycin-induced lung toxicity.
  • Furthermore, 3% of HL patients had an antecedent malignant hematological disease before occurrence of HL.
  • [MeSH-major] Hodgkin Disease / epidemiology. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Child. Child, Preschool. Combined Modality Therapy. Female. Hematologic Neoplasms. Humans. Infant. Male. Middle Aged. Neoplasms, Second Primary. Prognosis. Risk Factors. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18846373.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement